Video

Dr Richard Willke on Using Real-World Data to Inform Value-Based Contracts

There is a trend of making value-based deals to pay for treatments in order to ensure the drug works as advertised while also protecting payers from financial risk, explained Richard J. Willke, PhD, chief science officer of ISPOR.

There is a trend of making value-based deals to pay for treatments in order to ensure the drug works as advertised while also protecting payers from financial risk, explained Richard J. Willke, PhD, chief science officer of ISPOR.

Transcript

What is the importance of real-world data as more payers look to make value-based deals with pharma companies (such as the contracts Harvard Pilgrim signed with Eli Lilly for Forteo and Amgen for Enbrel)?

All I know about these agreements is what I’ve seen in the media, but they are part of a trend towards using real-world data to supply more information for these performance-based risk-sharing agreements. They generally base these agreements and the payments for these agreements on outcomes of treatment—and I think that’s the basis for the Enbrel deal—but they can be on another measure, like adherence, which as I understand is the basis for the Forteo deal.

Usually the underlying rationale is that the producer gets full payment if the treatment performs as advertised or as labeled. And if it doesn’t, then the payer is protected from some of the financial risk of the deal. The only way you know how it’s performing is to collect data on the outcomes, so most of these deals are accompanied by a careful data collection plan.

Related Videos
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Anna Mueller, MD, Mount Sinai
Marc Humbert, MD, PhD
Susan Cantrell, CEO of AMCP
John Ostrominski, MD
John Buse, MD, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo